From early access to national reimbursement – your partner for Swiss market access

At Swizzard Pharma, we provide hands-on market access services tailored to your product and the Swiss healthcare system.

Whether you’re pursuing early access via case-by-case reimbursement under Art. 71a–d KVV; shaping your pricing strategy; compiling your access dossier; or engaging with authorities such as the Federal Office of Public Health – we’re here to guide you.

Let’s work together to bring innovative therapies to patients in Switzerland.

---

Reach out to us for expert guidance on your strategic planning. Together, we can ensure a smooth regulatory and market access process, accelerating the availability of rare disease therapies to patients in need.

Michael Zürcher, Owner & CEO

Annabelle Müller, Market Access Director

Contact Us